Amplify Your Viral Vaccine Production with CRISPR/Cas9-Engineered Host Cells

3/12/2020


Abstract

Vaccines against viral infections like polio, chickenpox, measles, and viral hepatitis are manufactured by producing large quantities of viral particles in a scaled-up tissue culture system. A handful of historical cell lines like Vero (green monkey kidney) and MDCK (canine kidney) are approved by the FDA for viral vaccine production. However, other than clone selection and substrate adaption, relatively little has been done to improve the inherent viral production capacity of the cell lines. ATCC used CRISPR/Cas9 gene editing to create improved versions of cell lines commonly used for viral vaccine manufacturing. These cells produce model clinical viruses at titers 10-fold higher than the corresponding parental cell line, which has the potential to significantly reduce costs associated with virus and viral vaccine production.

Key Points

  • Most viral vaccines are manufactured in large-scale tissue culture systems using historical cell lines that are approved for vaccine manufacturing.
  • ATCC used CRISPR/Cas9 gene-editing techniques to increase the viral production efficiency of some of these historical cell lines.
  • These enhanced virus-producing cell lines have the potential to significantly reduce the costs associated with generating viral vaccines and high-titer viral stocks.

Presenters

Liz Gillies, Ph.D.

Liz Gillies, Ph.D.,
Scientist, ATCC Cell Systems

Dr. Gillies is a scientist in Cell Biology Research and Development at ATCC. She has more than eight years of experience using CRISPR/Cas9 gene-editing technologies to create advanced tissue culture models and systems. In her current role, she leads a small team developing enhanced bioproduction cell lines, including CRISPR/Cas9-engineered cell lines for enhanced viral vaccine production. She received her Ph.D. in Molecular Biophysics and Biochemistry from Yale in 2015.